Century Therapeutics to Present at the AACR Annual Meeting 2023

Rhea-AI Summary

Century Therapeutics (NASDAQ: IPSC) announced preclinical data from its iPSC-based cell therapy platform will be presented at the AACR Annual Meeting on April 17, 2023. The poster, titled 'iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysis', features abstract number 2914 and will be presented by Michael Hall, PhD from the company. This clinical-stage biotechnology firm focuses on developing innovative cell therapies to target cancer, leveraging adult stem cells to provide improved treatment options and broader patient access. For more details, visit Century Therapeutics.

PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company’s iPSC-based cell therapy platform will be presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 17, 2023.

Details of the poster presentation are as follows:

Abstract Number: 2914
Title: iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysis
Poster Board Number: 19
Session Title: Natural Killer and Natural Killer T Cell-based Cellular Therapies
Session Date: Monday, April 17, 2023
Session Time: 1:30 – 5:00 PM ET
Presenter: Michael Hall, PhD, Senior Scientist, Computational Immunology, Century Therapeutics

Full abstracts are currently available through the AACR conference website.

About Century Therapeutics
Century Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-stage biotechnology company harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit https://www.centurytx.com/.

Century Therapeutics Forward-Looking Statement
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to obtain FDA acceptance for our future IND submissions and commence clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic, geopolitical issues and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:
Company: Elizabeth Krutoholow – investor.relations@centurytx.com
Investors/Media: Melissa Forst/Maghan Meyers – century@argotpartners.com

FAQ

What is the date of the Century Therapeutics presentation at the AACR Annual Meeting?

The presentation will take place on April 17, 2023.

What is the title of the poster presented by Century Therapeutics?

The title is 'iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysis'.

Who is presenting the poster for Century Therapeutics?

The poster will be presented by Michael Hall, PhD.

What is the significance of the data presented by Century Therapeutics?

The data showcases advances in iPSC-derived cell therapies aimed at improving cancer treatment.

What does NASDAQ: IPSC refer to?

NASDAQ: IPSC is the stock symbol for Century Therapeutics.